<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical and histopathologic features of cutaneous adverse reactions associated with checkpoint inhibitor immunotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical and histopathologic features of cutaneous adverse reactions associated with checkpoint inhibitor immunotherapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical and histopathologic features of cutaneous adverse reactions associated with checkpoint inhibitor immunotherapy</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">CAE category</td> <td class="subtitle1">Cutaneous eruption</td> <td class="subtitle1">Time to onset</td> <td class="subtitle1">Clinical findings</td> <td class="subtitle1">Histopathology</td> </tr> <tr> <td rowspan="6"><strong>Inflammatory</strong></td> <td>Maculopapular (morbilliform)</td> <td>3 to 6 weeks</td> <td>Erythematous macules and flat papules on trunk and dorsal aspect of extremities</td> <td>Superficial, perivascular, lymphohistiocytic infiltrate +/– eosinophils.</td> </tr> <tr> <td>Eczematous</td> <td>0 to 3 weeks</td> <td>Pruritic, erythematous papules coalescing into plaques predominantly on trunk and extremities</td> <td>Spongiotic dermatitis with superficial, perivascular, lymphohistiocytic infiltrate +/– eosinophils.</td> </tr> <tr> <td>Psoriasiform</td> <td>0 to 3 weeks</td> <td>Well-demarcated, erythematous papules or plaques with adherent scale of the trunk and extremities (most common); palmoplantar, pustular, inverse, or guttate variations</td> <td>Regular acanthosis with hypogranulosis; confluent parakeratosis; and superficial, perivascular dermatitis with lymphocytes, histiocytes, and neutrophils.</td> </tr> <tr> <td>Lichenoid</td> <td>6 to 12 weeks</td> <td>Flat-topped, violaceous papules with adherent scale</td> <td>Lichenoid and vacuolar dermatitis with lymphocytes and histiocytes, hyperorthokeratosis, wedge-shaped hypergranulosis, and saw-tooth rete ridges.</td> </tr> <tr> <td>Granulomatous</td> <td>3 weeks or later</td> <td>Red-brown papules or nodules on the head, trunk, or extremities</td> <td>Nodular, histiocytic dermatitis with minimal surrounding lymphocytes or other inflammatory cells, negative special stains for organisms.</td> </tr> <tr> <td>Vitiligo</td> <td>7 to 16 weeks or later</td> <td>Depigmented macules and patches</td> <td>Decreased or absent melanocytes at the dermal-epidermal junction.</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Neoplastic</strong></td> <td>Cutaneous squamous cell carcinoma/keratoacanthoma</td> <td>12 to 18 weeks or later</td> <td>Hyperkeratotic papules and nodules</td> <td>Full-thickness epidermal atypia with a crateriform architecture in the case of keratoacanthoma.</td> </tr> <tr> <td rowspan="3"><strong>Severe cutaneous reactions</strong></td> <td>SJS/TEN</td> <td>1 to 4 weeks (may be shorter on re-exposure)</td> <td>Dusky red, coalescent, macular eruption, with atypical target lesions with central vesiculation and mucosal involvement</td> <td>Full-thickness epidermal necrosis with a sparse, superficial, perivascular, lymphohistiocytic infiltrate and possible vacuolar degeneration.</td> </tr> <tr> <td>DRESS</td> <td>2 to 8 weeks</td> <td> <p>Erythematous macules and papules (nonspecific cutaneous findings)</p> Facial edema and lymphadenopathy</td> <td>Interface dermatitis with basal vacuolization; spongiosis; perivascular, lymphocytic infiltrate; vascular damage.</td> </tr> <tr> <td>AGEP</td> <td>&lt;1 week</td> <td>Widespread erythema with numerous tiny, pinpoint pustules</td> <td>Spongiotic psoriasiform dermatitis with subcorneal pustules and numerous dermal eosinophils.</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2"><strong>Connective tissue disease</strong></td> <td>Dermatomyositis</td> <td>&gt;12 weeks</td> <td>Erythematous or violaceous papules in photodistribution "heliotrope eruption" (pink-violaceous erythema and edema of the eyelids)</td> <td>Sparse interface dermatitis with focal dyskeratosis and increased dermal mucin.</td> </tr> <tr class="highlight_lght_gray_text"> <td>Lupus erythematosus</td> <td>≥6 weeks</td> <td>Features of acute lupus erythematosus (eg, malar rash), subacute lupus erythematosus (erythematous papules and plaques; annular, polycyclic plaques on upper trunk, neck, and arms), or discoid lupus erythematosus (papulosquamous, photodistributed eruption)</td> <td>Superficial and deep, perivascular and periadnexal dermatitis with overlying interface dermatitis and increased dermal mucin.</td> </tr> <tr> <td><strong>Antibody mediated</strong></td> <td>Bullous pemphigoid</td> <td>13 to 16 weeks or later</td> <td>Prodromal pruritus followed by formation of tense vesicles</td> <td>Subepidermal, vesicular dermatitis with superficial, perivascular, and intravesicular eosinophils. Direct immunofluorescence positive for IgG and C3 at the dermal-epidermal junction.</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Hair</strong></td> <td>Alopecia areata</td> <td>13 to 16 weeks or later</td> <td>Round, alopecic patches on the scalp without scale or erythema</td> <td>Nonscarring alopecia with lymphocytic infiltrate at the base of the hair follicles.</td> </tr> <tr> <td rowspan="3"><strong>Rare, including possible exacerbation of pre-existing disease</strong></td> <td>Acneiform</td> <td>1 to 8 weeks or later</td> <td>Erythematous, follicular papules and pustules</td> <td>Acute neutrophilic folliculitis with disturbance of the follicular epithelium.</td> </tr> <tr> <td>Sweet syndrome</td> <td>≥4 weeks</td> <td>Erythematous, edematous, and tender plaques and nodules on face, upper extremities, and trunk</td> <td>Papillary dermal edema with minimal epidermal change and underlying, neutrophilic dermatitis without vasculitis.</td> </tr> <tr> <td>Pyoderma gangrenosum</td> <td>16 weeks(?)</td> <td>Inflammatory papule, pustule, or nodule that subsequently enlarges and ulcerates with undermined, violaceous borders</td> <td>Diffuse, neutrophilic, dermal infiltrate often with fibrosis, granulation tissue, and negative tissue cultures and/or special stains for organisms.</td> </tr> </tbody></table></div><div class="graphic_footnotes">AGEP: acute generalized exanthematous pustulosis; C3: complement component 3; CAE: cutaneous adverse event; DRESS: drug reaction with eosinophilia and systemic symptoms; IgG: immunoglobulin G; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis.</div><div id="graphicVersion">Graphic 131015 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
